"RIV/00064173:_____/13:#0000366" . "RIV/00064173:_____/13:#0000366!RIV14-MZ0-00064173" . . . "78" . "Position of targeted therapy in ovarian cancer management"@en . "4"^^ . "C\u00EDl studie: Podat aktu\u00E1ln\u00ED p\u0159ehled problematiky vyu\u017Eit\u00ED c\u00EDlen\u00E9 l\u00E9\u010Dby u ovari\u00E1ln\u00EDho karcinomu. Metodika: Po zpracov\u00E1n\u00ED sou\u010Dasn\u00E9 literatury \u2013 publikovan\u00FDch studi\u00ED a statistick\u00FDch \u00FAdaj\u016F z \u010Cesk\u00E9 republiky p\u0159edkl\u00E1d\u00E1me aktu\u00E1ln\u00ED pohled na danou problematiku. V\u00FDsledky: Karcinomy ovari\u00ED jsou v \u010Cesk\u00E9 republice mezi gynekologick\u00FDmi zhoubn\u00FDmi n\u00E1dory onemocn\u011Bn\u00EDm s nejvy\u0161\u0161\u00ED mortalitou. U v\u011Bt\u0161iny pacientek je n\u00E1dor diagnostikov\u00E1n v pokro\u010Dil\u00E9m stadiu. Prim\u00E1rn\u00ED l\u00E9\u010Dba je zalo\u017Eena na kombinaci radik\u00E1ln\u00ED resekce a adjuvantn\u00ED chemoterapie. V\u00EDce ne\u017E u dvou t\u0159etin p\u0159\u00EDpad\u016F doch\u00E1z\u00ED d\u0159\u00EDve nebo pozd\u011Bji k recidiv\u011B n\u00E1doru, velice \u010Dasto bez mo\u017Enosti vyl\u00E9\u010Den\u00ED. Neuspokojiv\u00E9 v\u00FDsledky standardn\u00ED l\u00E9\u010Dby jsou d\u016Fvodem hled\u00E1n\u00ED \u00FA\u010Dinn\u011Bj\u0161\u00EDch postup\u016F. Z\u00E1v\u011Br: P\u0159edm\u011Btem v\u00FDzkumu posledn\u00EDch let je c\u00EDlen\u00E1 l\u00E9\u010Dba. Byl prok\u00E1z\u00E1n p\u0159\u00EDzniv\u00FD vliv bevacizumabu, jen\u017E inhibic\u00ED n\u00E1dorov\u00E9 angiogeneze vede k prodlou\u017Een\u00ED intervalu do progrese n\u00E1doru"@cs . "4" . . "[0291739B78EC]" . "I, V" . "Ovarian cancer in Czech Republic takes first place in mortality among gynecological malignant tumours. In most cases it is diagnosed in advanced stages. Initial treatment is based on combination of radical surgery and adjuvant chemotherapy. In more than two thirds of cases ovarian cancer relapses sooner or later, very often without a chance to cure the patient. Unsatisfying result of standard treatment is reason of looking for more effective procedures. Targeted the- rapy is subject of research in last years. Positive effect of bevacizumab has been proved. Through inhibition of angiogenesis it leads to prolonging of interval to cancer progression"@en . "2"^^ . "Postaven\u00ED c\u00EDlen\u00E9 l\u00E9\u010Dby v managementu ovari\u00E1ln\u00EDho karcinomu" . . . "C\u00EDl studie: Podat aktu\u00E1ln\u00ED p\u0159ehled problematiky vyu\u017Eit\u00ED c\u00EDlen\u00E9 l\u00E9\u010Dby u ovari\u00E1ln\u00EDho karcinomu. Metodika: Po zpracov\u00E1n\u00ED sou\u010Dasn\u00E9 literatury \u2013 publikovan\u00FDch studi\u00ED a statistick\u00FDch \u00FAdaj\u016F z \u010Cesk\u00E9 republiky p\u0159edkl\u00E1d\u00E1me aktu\u00E1ln\u00ED pohled na danou problematiku. V\u00FDsledky: Karcinomy ovari\u00ED jsou v \u010Cesk\u00E9 republice mezi gynekologick\u00FDmi zhoubn\u00FDmi n\u00E1dory onemocn\u011Bn\u00EDm s nejvy\u0161\u0161\u00ED mortalitou. U v\u011Bt\u0161iny pacientek je n\u00E1dor diagnostikov\u00E1n v pokro\u010Dil\u00E9m stadiu. Prim\u00E1rn\u00ED l\u00E9\u010Dba je zalo\u017Eena na kombinaci radik\u00E1ln\u00ED resekce a adjuvantn\u00ED chemoterapie. V\u00EDce ne\u017E u dvou t\u0159etin p\u0159\u00EDpad\u016F doch\u00E1z\u00ED d\u0159\u00EDve nebo pozd\u011Bji k recidiv\u011B n\u00E1doru, velice \u010Dasto bez mo\u017Enosti vyl\u00E9\u010Den\u00ED. Neuspokojiv\u00E9 v\u00FDsledky standardn\u00ED l\u00E9\u010Dby jsou d\u016Fvodem hled\u00E1n\u00ED \u00FA\u010Dinn\u011Bj\u0161\u00EDch postup\u016F. Z\u00E1v\u011Br: P\u0159edm\u011Btem v\u00FDzkumu posledn\u00EDch let je c\u00EDlen\u00E1 l\u00E9\u010Dba. Byl prok\u00E1z\u00E1n p\u0159\u00EDzniv\u00FD vliv bevacizumabu, jen\u017E inhibic\u00ED n\u00E1dorov\u00E9 angiogeneze vede k prodlou\u017Een\u00ED intervalu do progrese n\u00E1doru" . "Kubecov\u00E1, Martina" . "4"^^ . . . . "\u010Cesk\u00E1 gynekologie" . . . "QALY; bevacizumab; targeted therapy; ovarian cancer"@en . "Postaven\u00ED c\u00EDlen\u00E9 l\u00E9\u010Dby v managementu ovari\u00E1ln\u00EDho karcinomu"@cs . . "CZ - \u010Cesk\u00E1 republika" . "Kindlov\u00E1, Eva" . . . . "Position of targeted therapy in ovarian cancer management"@en . "Postaven\u00ED c\u00EDlen\u00E9 l\u00E9\u010Dby v managementu ovari\u00E1ln\u00EDho karcinomu" . "97665" . . . "Postaven\u00ED c\u00EDlen\u00E9 l\u00E9\u010Dby v managementu ovari\u00E1ln\u00EDho karcinomu"@cs . . "http://www.prolekare.cz/ceska-gynekologie-clanek/postaveni-cilene-lecby-v-managementu-ovarialniho-karcinomu-41438" . . "1210-7832" .